Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A44711 | 27633289 | Curr Vasc Pharmacol | Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? | 2016 | Details |
| A44712 | 27626470 | Clinics (Sao Paulo) | Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey. | 2016 | Details |
| A44713 | 27625607 | Front Pharmacol | Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury. | 2016 | Details |
| A44714 | 27615179 | Med Sci (Paris) | [Sphingosine kinase-1: role in non alcoholic fatty liver disease]. | 2016 | Details |
| A44715 | 27612218 | Z Gastroenterol | Causes of altered liver function tests - the role of alpha-1 antitrypsin. | 2016 | Details |
| A44716 | 27605111 | BMJ | Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. | 2016 | Details |
| A44717 | 27600939 | Alcohol Alcohol | Alcohol and Liver Transplantation. | 2016 | Details |
| A44718 | 27594084 | Metabolism | Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. | 2016 | Details |
| A44719 | 27587085 | Exp Mol Pathol | Alcoholic steatohepatitis (ASH) causes more UPR-ER stress than non-alcoholic steatohepatitis (NASH). | 2016 | Details |
| A44720 | 30169948 | Nihon Naika Gakkai Zasshi | [113th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Diagnosis and Management of Non-alcoholic Fatty Liver Diseases and Non-alcoholic Steatohepatitis: Current Concepts | 2016 | Details |
| A44721 | 29737646 | Diabetes Self Manag | THE HEPATITIS/DIABETES CONNECTION The Effect of Hep C cures on Type 2 diabetes still unknown. | 2016 | Details |
| A44722 | 27574587 | J Hepatocell Carcinoma | Hepatocellular carcinoma in elderly patients: challenges and solutions. | 2016 | Details |
| A44723 | 27560811 | Praxis (Bern 1994) | [Not Available]. | 2016 | Details |
| A44724 | 27550974 | Circulation | Added Sugars and Cardiovascular Disease Risk in Children: A Scientific Statement From the American Heart Association. | 2016 | Details |
| A44725 | 27546703 | Bratisl Lek Listy | The efficacy of Mediterranean diet in non-alcoholic fatty liver disease. | 2016 | Details |
| A44726 | 27534992 | J Lipid Res | Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. | 2016 | Details |
| A44727 | 27521986 | J Pharm Biomed Anal | Chemical profiling of San-Huang decoction by UPLC-ESI-Q-TOF-MS. | 2016 | Details |
| A44728 | 27520876 | J Hepatol | The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. | 2016 | Details |
| A44729 | 27512925 | Liver Int | Gamma-glutamyltransferase-friend or foe within? | 2016 | Details |
| A44730 | 27511913 | Toxicol Appl Pharmacol | Hepatocyte-protective effect of nectandrin B, a nutmeg lignan, against oxidative stress: Role of Nrf2 activation through ERK phosphorylation and AMPK-dependent inhibition of GSK-3β. | 2016 | Details |
| A44731 | 27501737 | J Hepatol | Nocturnal hypoxia in obese-related obstructive sleep apnea as a putative trigger of oxidative stress in pediatric NAFLD progression. | 2016 | Details |
| A44732 | 27499712 | Gastroenterol Hepatol (N Y) | Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. | 2016 | Details |
| A44733 | 27498134 | J Hepatol | Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease. | 2016 | Details |
| A44734 | 27498133 | J Hepatol | Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease". | 2016 | Details |
| A44735 | 27497142 | Diabetes Res Clin Pract | Proposed cut-off value of the intrahepatic lipid content for metabolically normal persons assessed by proton magnetic resonance spectroscopy in a Japanese population. | 2016 | Details |
| A44736 | 27493121 | Ann Hepatol |  How to screen NAFLD patients for diabetes? | 2017 | Details |
| A44737 | 27486346 | J Blood Med | Clinical applications of therapeutic phlebotomy. | 2016 | Details |
| A44738 | 27484935 | Aliment Pharmacol Ther | Editorial: dark chocolate may improve NAFLD and metabolic syndrome by reducing oxidative stress. | 2016 | Details |
| A44739 | 27484243 | Food Chem Toxicol | Hepatoprotection and hepatotoxicity of Heshouwu, a Chinese medicinal herb: Context of the paradoxical effect. | 2016 | Details |
| A44740 | 27483691 | Versicherungsmedizin | [Not Available]. | 2016 | Details |
| A44741 | 27480541 | Lipids Health Dis | Erratum to: Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events? | 2016 | Details |
| A44742 | 27480034 | Lancet Diabetes Endocrinol | Research digest: NAFLD in the spotlight. | 2016 | Details |
| A44743 | 27477396 | Intern Med | Relationship between Non-alcoholic Fatty Liver Disease and Thyroid Dysfunction. | 2016 | Details |
| A44744 | 27477080 | Transl Res | Gut microbiome and liver disease. | 2016 | Details |
| A44745 | 27468739 | Dig Dis Sci | Nonalcoholic Fatty Liver Disease in Patients with Autoimmune Hepatitis: Further Reason for Teeth GNASHing? | 2016 | Details |
| A44746 | 27458858 | Turk J Gastroenterol | Non-alcoholic fatty liver disease in chronic hepatitis B patients. | 2016 | Details |
| A44747 | 27449495 | Drug Saf | Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. | 2016 | Details |
| A44748 | 31041057 | Clin Liver Dis (Hoboken) | In search of new biomarkers for nonalcoholic fatty liver disease. | 2016 | Details |
| A44749 | 27448055 | Nat Rev Endocrinol | Liver: Exercising to reduce risk factors in NAFLD. | 2016 | Details |
| A44751 | 27438430 | Arq Gastroenterol | IS ARFI A USEFUL TOOL FOR NON-INVASIVE EVALUATION OF LIVER STIFFNESS IN NONALCOHOLIC FATTY LIVER DISEASE AND HEPATITIS C? | 2016 | Details |
| A44752 | 27436271 | Gut | Emerging role of miR-21 in non-alcoholic fatty liver disease. | 2016 | Details |
| A44753 | 27435326 | Dig Dis Sci | Underutilization of Statin Therapy Among Patients with NAFLD in the USA: Validation with Big Data. | 2016 | Details |
| A44754 | 27432221 | Mol Nutr Food Res | Prolonged feeding with green tea polyphenols exacerbates cholesterol-induced fatty liver disease in mice. | 2016 | Details |
| A44755 | 27423982 | Eur J Intern Med | Homocysteine in nonalcoholic steatohepatitis: A reply. | 2016 | Details |
| A44756 | 27423933 | Endocrinol Nutr | Nonalcoholic steatohepatitis and diabetes. | 2016 | Details |
| A44757 | 27422790 | Endocrine | Two-hour postload glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study. | 2016 | Details |
| A44758 | 27419149 | Open Forum Infect Dis | Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus. | 2016 | Details |
| A44759 | 27407045 | Nat Rev Gastroenterol Hepatol | NAFLD: Severity of NAFLD in patients who are not obese. | 2016 | Details |
| A44760 | 27401791 | J Hepatol | How to diagnose NAFLD in 2016. | 2016 | Details |
| A44761 | 27392426 | J Hepatol | Exercise in NAFLD: Just do it. | 2016 | Details |
| A44762 | 27391855 | ACS Chem Biol | Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism. | 2016 | Details |
| A44763 | 27388553 | Hepatology | Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges. | 2016 | Details |
| A44764 | 27385159 | Diabetes | Inhibition of Pyruvate Dehydrogenase Kinase 2 Protects Against Hepatic Steatosis Through Modulation of Tricarboxylic Acid Cycle Anaplerosis and Ketogenesis. | 2016 | Details |
| A44765 | 27384446 | Ann Clin Biochem | Gamma glutamyl transferase 'To be or not to be' a liver function test? | 2016 | Details |
| A44766 | 27380587 | JAMA Intern Med | Moderate Exercise for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A44767 | 27366215 | Therap Adv Gastroenterol | Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. | 2016 | Details |
| A44768 | 27364225 | Alcohol Clin Exp Res | Microbiota and Alcoholic Liver Disease. | 2016 | Details |
| A44769 | 27364051 | J Am Coll Cardiol | Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes. | 2016 | Details |
| A44770 | 27363234 | Adolesc Med State Art Rev | Liver Disease in Adolescents. | 2016 | Details |
| A44771 | 27358840 | J Lifestyle Med | Body Composition and Non-alcoholic Fatty Liver Disease. | 2016 | Details |
| A44772 | 27353403 | Nat Rev Gastroenterol Hepatol | Obesity: Metabolically healthy obesity and NAFLD. | 2016 | Details |
| A44773 | 27353275 | Eur J Intern Med | High levels of serum homocysteine in non-alcoholic steatohepatitis. | 2016 | Details |
| A44774 | 27351453 | Hepatology | G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. | 2016 | Details |
| A44775 | 27347902 | Compr Physiol | Functions of the Gallbladder. | 2016 | Details |
| A44776 | 27347126 | Oncol Lett | Elovl6 is a poor prognostic predictor in breast cancer. | 2016 | Details |
| A44777 | 27339885 | Nat Rev Endocrinol | Thyroid function: Poor thyroid function linked to NAFLD. | 2016 | Details |
| A44778 | 27339672 | Crit Care Clin | Acute-on-chronic and Decompensated Chronic Liver Failure: Definitions, Epidemiology, and Prognostication. | 2016 | Details |
| A44779 | 27334756 | Mol Cell Biochem | Annexin A6 protein is downregulated in human hepatocellular carcinoma. | 2016 | Details |
| A44780 | 27332079 | Med Sci Monit | The Role of Iron and Iron Overload in Chronic Liver Disease. | 2016 | Details |
| A44781 | 27322943 | Ann Intern Med | Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes. | 2016 | Details |
| A44782 | 27322890 | Ann Intern Med | Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis? | 2016 | Details |
| A44783 | 27320364 | J Hepatol | Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood. | 2016 | Details |
| A44784 | 27318725 | Cells Tissues Organs | Short Exposure to a High-Sucrose Diet and the First 'Hit' of Nonalcoholic Fatty Liver Disease in Mice. | 2016 | Details |
| A44785 | 29546172 | AIMS Public Health | Beneficial Role of Coffee and Caffeine in Neurodegenerative Diseases: A Minireview. | 2016 | Details |
| A44786 | 27313633 | Hepat Mon | Comments on "The Effects of Aerobic and Resistance Exercise Training on Liver Enzymes and Hepatic Fat in Iranian Men With Nonalcoholic Fatty Liver Disease". | 2016 | Details |
| A44787 | 27312304 | Lancet | Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply. | 2016 | Details |
| A44788 | 27312303 | Lancet | Liraglutide for patients with non-alcoholic steatohepatitis. | 2016 | Details |
| A44789 | 27312302 | Lancet | Liraglutide for patients with non-alcoholic steatohepatitis. | 2016 | Details |
| A44790 | 27305911 | J Mol Cell Biol | Exploring complex diseases through translational research. | 2016 | Details |
| A44791 | 27293541 | Ther Adv Endocrinol Metab | Osteoporosis in liver disease: pathogenesis and management. | 2016 | Details |
| A44792 | 27291253 | Future Cardiol | Nonalcoholic fatty liver disease is associated with coronary artery disease and subclinical atherosclerosis. | 2016 | Details |
| A44793 | 27287457 | Hepatology | Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy. | 2016 | Details |
| A44794 | 27266135 | Nihon Rinsho | [Liver disease (NAFLD, NASH)]. | 2016 | Details |
| A44795 | 27266045 | Nihon Naika Gakkai Zasshi | [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: VIII. The prognosis and follow-up]. | 2016 | Details |
| A44796 | 27266044 | Nihon Naika Gakkai Zasshi | [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: VII. Routine treatment: when referring to specialists]. | 2016 | Details |
| A44797 | 27266043 | Nihon Naika Gakkai Zasshi | [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: VI. Diagnostic procedures: when referring to specialists]. | 2016 | Details |
| A44798 | 27266042 | Nihon Naika Gakkai Zasshi | [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: V. Extrahepatic manifestations: cerebral and cardiovascular diseases, chronic kidney disease]. | 2016 | Details |
| A44799 | 27266041 | Nihon Naika Gakkai Zasshi | [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: IV. Relation of NAFLD with lifestyle-related disease including obesity, dyslipidemia and hypertension]. | 2016 | Details |
| A44800 | 27266040 | Nihon Naika Gakkai Zasshi | [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: III. Relation with Type II diabetes: regulation by hepatokines]. | 2016 | Details |
| A44801 | 27266039 | Nihon Naika Gakkai Zasshi | [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: II. Complexity in pathogenesis of nonalcoholic fatty liver disease]. | 2016 | Details |
| A44802 | 27266038 | Nihon Naika Gakkai Zasshi | [linical Importance of Non-alcoholic Fatty Liver Diseases. Topics II Clinical impact of epidemiological studies]. | 2016 | Details |
| A44803 | 27266037 | Nihon Naika Gakkai Zasshi | [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Editorial: Fatty liver important?]. | 2016 | Details |
| A44804 | 27264097 | J Nutr Sci Vitaminol (Tokyo) | Strong Inhibition of Secretory Sphingomyelinase by Catechins, Particularly by (-)-Epicatechin 3-O-Gallate and (-)-3'-O-Methylepigallocatechin 3-O-Gallate. | 2016 | Details |
| A44805 | 27262537 | Nutr Res | Mulberry ethanol extract attenuates hepatic steatosis and insulin resistance in high-fat diet-fed mice. | 2016 | Details |
| A44806 | 27256522 | Clin Endocrinol (Oxf) | Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. | 2016 | Details |
| A44807 | 27254536 | Eur J Gastroenterol Hepatol | Fracture risk calculation tool enhances dual-energy X-ray absorptiometry scan referral pathway in cirrhosis patients. | 2016 | Details |
| A44808 | 27252163 | Physiology (Bethesda) | Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. | 2016 | Details |
| A44809 | 27243019 | Inflamm Intest Dis | Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West? | 2016 | Details |
| A44810 | 27241654 | Indian J Med Res | Wiser to prevent childhood obesity. | 2016 | Details |
| A44811 | 27239763 | Hepatology | Hepatocyte mitochondrial DNA released in microparticles and toll-like receptor 9 activation: A link between lipotoxicity and inflammation during nonalcoholic steatohepatitis. | 2016 | Details |